BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

280 related articles for article (PubMed ID: 22090452)

  • 21. DNA methylation profiling of medulloblastoma allows robust subclassification and improved outcome prediction using formalin-fixed biopsies.
    Schwalbe EC; Williamson D; Lindsey JC; Hamilton D; Ryan SL; Megahed H; Garami M; Hauser P; Dembowska-Baginska B; Perek D; Northcott PA; Taylor MD; Taylor RE; Ellison DW; Bailey S; Clifford SC
    Acta Neuropathol; 2013 Mar; 125(3):359-71. PubMed ID: 23291781
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment of Children and Adolescents With Metastatic Medulloblastoma and Prognostic Relevance of Clinical and Biologic Parameters.
    von Bueren AO; Kortmann RD; von Hoff K; Friedrich C; Mynarek M; Müller K; Goschzik T; Zur Mühlen A; Gerber N; Warmuth-Metz M; Soerensen N; Deinlein F; Benesch M; Zwiener I; Kwiecien R; Faldum A; Bode U; Fleischhack G; Hovestadt V; Kool M; Jones D; Northcott P; Kuehl J; Pfister S; Pietsch T; Rutkowski S
    J Clin Oncol; 2016 Dec; 34(34):4151-4160. PubMed ID: 27863192
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Chromosome 17 alterations identify good-risk and poor-risk tumors independently of clinical factors in medulloblastoma.
    McCabe MG; Bäcklund LM; Leong HS; Ichimura K; Collins VP
    Neuro Oncol; 2011 Apr; 13(4):376-83. PubMed ID: 21292688
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Subgroup and subtype-specific outcomes in adult medulloblastoma.
    Coltin H; Sundaresan L; Smith KS; Skowron P; Massimi L; Eberhart CG; Schreck KC; Gupta N; Weiss WA; Tirapelli D; Carlotti C; Li KKW; Ryzhova M; Golanov A; Zheludkova O; Absalyamova O; Okonechnikov K; Stichel D; von Deimling A; Giannini C; Raskin S; Van Meir EG; Chan JA; Fults D; Chambless LB; Kim SK; Vasiljevic A; Faure-Conter C; Vibhakar R; Jung S; Leary S; Mora J; McLendon RE; Pollack IF; Hauser P; Grajkowska WA; Rubin JB; van Veelen MC; French PJ; Kros JM; Liau LM; Pfister SM; Kool M; Kijima N; Taylor MD; Packer RJ; Northcott PA; Korshunov A; Ramaswamy V
    Acta Neuropathol; 2021 Nov; 142(5):859-871. PubMed ID: 34409497
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Subgroup-specific prognostic signaling and metabolic pathways in pediatric medulloblastoma.
    Park AK; Lee JY; Cheong H; Ramaswamy V; Park SH; Kool M; Phi JH; Choi SA; Cavalli F; Taylor MD; Kim SK
    BMC Cancer; 2019 Jun; 19(1):571. PubMed ID: 31185958
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Exclusive Hyperfractionated Radiation Therapy and Reduced Boost Volume for Standard-Risk Medulloblastoma: Pooled Analysis of the 2 French Multicentric Studies MSFOP98 and MSFOP 2007 and Correlation With Molecular Subgroups.
    Carrie C; Kieffer V; Figarella-Branger D; Masliah-Planchon J; Bolle S; Bernier V; Laprie A; Supiot S; Leseur J; Habrand JL; Alapetite C; Kerr C; Dufour C; Claude L; Chapet S; Huchet A; Bondiau PY; Escande A; Truc G; Nguyen TD; Pasteuris C; Vigneron C; Muracciole X; Bourdeaut F; Appay R; Dubray B; Colin C; Ferlay C; Dussart S; Chabaud S; Padovani L; ;
    Int J Radiat Oncol Biol Phys; 2020 Dec; 108(5):1204-1217. PubMed ID: 32768563
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prognostic significance of clinical, histopathological, and molecular characteristics of medulloblastomas in the prospective HIT2000 multicenter clinical trial cohort.
    Pietsch T; Schmidt R; Remke M; Korshunov A; Hovestadt V; Jones DT; Felsberg J; Kaulich K; Goschzik T; Kool M; Northcott PA; von Hoff K; von Bueren AO; Friedrich C; Mynarek M; Skladny H; Fleischhack G; Taylor MD; Cremer F; Lichter P; Faldum A; Reifenberger G; Rutkowski S; Pfister SM
    Acta Neuropathol; 2014 Jul; 128(1):137-49. PubMed ID: 24791927
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical and molecular stratification of disease risk in medulloblastoma.
    Gilbertson R; Wickramasinghe C; Hernan R; Balaji V; Hunt D; Jones-Wallace D; Crolla J; Perry R; Lunec J; Pearson A; Ellison D
    Br J Cancer; 2001 Sep; 85(5):705-12. PubMed ID: 11531256
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prognostic significance of chromosome 17p deletions in childhood primitive neuroectodermal tumors (medulloblastomas) of the central nervous system.
    Biegel JA; Janss AJ; Raffel C; Sutton L; Rorke LB; Harper JM; Phillips PC
    Clin Cancer Res; 1997 Mar; 3(3):473-8. PubMed ID: 9815707
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical and mutational profiles of adult medulloblastoma groups.
    Wong GC; Li KK; Wang WW; Liu AP; Huang QJ; Chan AK; Poon MF; Chung NY; Wong QH; Chen H; Chan DTM; Liu XZ; Mao Y; Zhang ZY; Shi ZF; Ng HK
    Acta Neuropathol Commun; 2020 Nov; 8(1):191. PubMed ID: 33172502
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Real-time PCR assay based on the differential expression of microRNAs and protein-coding genes for molecular classification of formalin-fixed paraffin embedded medulloblastomas.
    Kunder R; Jalali R; Sridhar E; Moiyadi A; Goel N; Goel A; Gupta T; Krishnatry R; Kannan S; Kurkure P; Deopujari C; Shetty P; Biyani N; Korshunov A; Pfister SM; Northcott PA; Shirsat NV
    Neuro Oncol; 2013 Dec; 15(12):1644-51. PubMed ID: 24203893
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Biomarker-driven stratification of disease-risk in non-metastatic medulloblastoma: Results from the multi-center HIT-SIOP-PNET4 clinical trial.
    Clifford SC; Lannering B; Schwalbe EC; Hicks D; O'Toole K; Nicholson SL; Goschzik T; Zur Mühlen A; Figarella-Branger D; Doz F; Rutkowski S; Gustafsson G; Pietsch T;
    Oncotarget; 2015 Nov; 6(36):38827-39. PubMed ID: 26420814
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Second-generation molecular subgrouping of medulloblastoma: an international meta-analysis of Group 3 and Group 4 subtypes.
    Sharma T; Schwalbe EC; Williamson D; Sill M; Hovestadt V; Mynarek M; Rutkowski S; Robinson GW; Gajjar A; Cavalli F; Ramaswamy V; Taylor MD; Lindsey JC; Hill RM; Jäger N; Korshunov A; Hicks D; Bailey S; Kool M; Chavez L; Northcott PA; Pfister SM; Clifford SC
    Acta Neuropathol; 2019 Aug; 138(2):309-326. PubMed ID: 31076851
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inhibition of BRD4 attenuates tumor cell self-renewal and suppresses stem cell signaling in MYC driven medulloblastoma.
    Venkataraman S; Alimova I; Balakrishnan I; Harris P; Birks DK; Griesinger A; Amani V; Cristiano B; Remke M; Taylor MD; Handler M; Foreman NK; Vibhakar R
    Oncotarget; 2014 May; 5(9):2355-71. PubMed ID: 24796395
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Childhood tumors of the nervous system as disorders of normal development.
    Grimmer MR; Weiss WA
    Curr Opin Pediatr; 2006 Dec; 18(6):634-8. PubMed ID: 17099362
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rapid diagnosis of medulloblastoma molecular subgroups.
    Schwalbe EC; Lindsey JC; Straughton D; Hogg TL; Cole M; Megahed H; Ryan SL; Lusher ME; Taylor MD; Gilbertson RJ; Ellison DW; Bailey S; Clifford SC
    Clin Cancer Res; 2011 Apr; 17(7):1883-94. PubMed ID: 21325292
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Correlation of chromosome 17p loss with clinical outcome in medulloblastoma.
    Emadian SM; McDonald JD; Gerken SC; Fults D
    Clin Cancer Res; 1996 Sep; 2(9):1559-64. PubMed ID: 9816333
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Medulloblastoma: clinicopathological correlates of SHH, WNT, and non-SHH/WNT molecular subgroups.
    Ellison DW; Dalton J; Kocak M; Nicholson SL; Fraga C; Neale G; Kenney AM; Brat DJ; Perry A; Yong WH; Taylor RE; Bailey S; Clifford SC; Gilbertson RJ
    Acta Neuropathol; 2011 Mar; 121(3):381-96. PubMed ID: 21267586
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Single nCounter assay for prediction of MYCN amplification and molecular classification of medulloblastomas: a multicentric study.
    Moreno DA; da Silva LS; Zanon MF; Bonatelli M; de Paula FE; de Medeiros Matsushita M; Teixeira GR; Santana IVV; Saggioro F; Neder L; Stavale JN; Malheiros SMF; Lima M; Hajj GNM; Garcia-Rivello H; Christiansen S; Nunes S; da Costa MJG; Soares MJ; Pinheiro J; Junior CA; Mançano BM; Reis RM
    J Neurooncol; 2022 Mar; 157(1):27-35. PubMed ID: 35166989
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Medulloblastoma with transitional features between Group 3 and Group 4 is associated with good prognosis.
    Łastowska M; Trubicka J; Niemira M; Paczkowska-Abdulsalam M; Karkucińska-Więckowska A; Kaleta M; Drogosiewicz M; Perek-Polnik M; Krętowski A; Cukrowska B; Grajkowska W; Dembowska-Bagińska B; Matyja E
    J Neurooncol; 2018 Jun; 138(2):231-240. PubMed ID: 29427151
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.